Katherine M. Bell‐McGuinn

Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer: a proof-of-concept trial

M. William Audeh, James Carmichael, Richard T. Penson et al. · The Lancet · 2010 · 2.3K citations

Medicine, Cancer Management, Gynecology +7

Rucaparib in relapsed, platinum-sensitive high-grade ovarian carcinoma (ARIEL2 Part 1): an international, multicentre, open-label, phase 2 trial

Elizabeth M. Swisher, Kevin Lin, Amit M. Oza et al. · The Lancet Oncology · 2016 · 1.2K citations · Full text

Medicine, Pharmacology, Pathology +6

Veliparib with First-Line Chemotherapy and as Maintenance Therapy in Ovarian Cancer

Robert L. Coleman, Gini F. Fleming, Mark F. Brady et al. · New England Journal of Medicine · 2019 · 886 citations · Full text

Macrophages and cathepsin proteases blunt chemotherapeutic response in breast cancer

Tanaya Shree, Oakley C. Olson, Benelita T. Elie et al. · Genes & Development · 2011 · 527 citations · Full text

Breast Oncology, S. Macrophages, Chemoprevention Strategy +17

Phase II, Open-Label, Randomized, Multicenter Study Comparing the Efficacy and Safety of Olaparib, a Poly (ADP-Ribose) Polymerase Inhibitor, and Pegylated Liposomal Doxorubicin in Patients With <i>BRCA1</i> or <i>BRCA2</i> Mutations and Recurrent Ovarian Cancer

Stan B. Kaye, Jan Lubiński, Ursula A. Matulonis et al. · Journal of Clinical Oncology · 2011 · 472 citations